NeoGenomics (NASDAQ:NEO) Announces Quarterly Earnings Results

NeoGenomics (NASDAQ:NEO) issued its quarterly earnings data on Wednesday. The medical research company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01, FiscalAI reports. NeoGenomics had a negative return on equity of 0.98% and a negative net margin of 4.10%. The firm had revenue of $209.25 million for the quarter, compared to analyst estimates of $206.70 million. During the same period in the prior year, the firm posted $0.03 EPS. The company’s revenue for the quarter was up 11.3% on a year-over-year basis.

Here are the key takeaways from NeoGenomics’ conference call:

• Strong third-quarter performance led management to raise 2026 guidance: revenue is now expected at $807–$809 million and adjusted EBITDA at approximately $60 million. Total revenue grew 11% year over year to $209 million, while adjusted EBITDA increased 53% to $18.7 million.
• NGS remained the primary growth engine, with revenue up 29% and volumes up 17%; large-panel volumes grew more than 25%. Management cited new products, higher-value testing, payer wins, customer-interface improvements, and sales-force expansion as drivers of continued growth and further AUP upside.
• RaDaR ST’s reimbursement and adoption footprint is expanding after MolDX coverage for immunotherapy monitoring, with two additional indications under review and a commercial payer expected to cover all MolDX-reimbursed indications starting December 15. Management reported improving monthly volumes and a roughly 30% attachment rate to other NeoGenomics tests, though more meaningful revenue is expected in 2028 and beyond.
• The non-clinical business declined about 10% year over year, pressured by legacy, lower-margin pharma contracts that the company is evaluating or exiting. Near-term profitability also faces potential 2027 PAMA pressure, unreimbursed MRD testing costs, and temporary receivables effects from the XiFin revenue-cycle-management implementation.
• Warren Stone will become CEO on January 4, 2027, while Tony Zook becomes Executive Chair. Management emphasized strategic continuity and plans to provide a broader 2027 outlook, including an investor day, in the first half of next year.

NeoGenomics Stock Performance

NEO stock opened at $17.93 on Friday. The company has a fifty day moving average price of $17.67 and a 200-day moving average price of $12.80. NeoGenomics has a 52-week low of $7.07 and a 52-week high of $20.15. The company has a quick ratio of 3.35, a current ratio of 3.60 and a debt-to-equity ratio of 0.48.

Key NeoGenomics News

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q3 results beat expectations: NeoGenomics reported adjusted EPS of $0.07 versus the $0.06 consensus estimate and revenue of $209.25 million versus expectations of $206.70 million. Revenue increased 11.3% year over year, while EPS improved from $0.03 in the prior-year quarter. NeoGenomics Q3 earnings report
• Positive Sentiment: Full-year outlook raised: Management lifted 2026 revenue guidance to approximately $807 million-$809 million, reinforcing expectations for continued growth and helping improve investor sentiment. NeoGenomics raises 2026 guidance
• Positive Sentiment: Analyst support remains strong: BTIG Research reaffirmed its “Buy” rating and maintained a $28 price target, implying substantial potential upside from the quoted share price. BTIG Research rating
• Neutral Sentiment: CEO transition planned: NeoGenomics expects a leadership change in January 2027. The transition could create near-term uncertainty, but it may also be viewed as orderly because it was disclosed alongside the stronger outlook. NeoGenomics CEO transition and guidance
• Negative Sentiment: Profitability remains a concern: Despite the earnings beat, the company reported a negative net margin and negative return on equity, meaning investors may want evidence that revenue growth will translate into sustainable profitability.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NEO shares. Piper Sandler reaffirmed an “overweight” rating on shares of NeoGenomics in a research report on Wednesday, October 7th. Benchmark raised their target price on NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, July 24th. Needham & Company LLC lifted their target price on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. BTIG Research reissued a “buy” rating and set a $28.00 target price on shares of NeoGenomics in a research note on Thursday. Finally, Craig Hallum restated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $20.88.

NeoGenomics Company Profile

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.